[Other] Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Marilena Post time 2024-6-13 20:43:36 | Show all posts |Read mode
Reward10points




Best Answer

Please adopt

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
fenavi Post time 2024-6-13 20:43:37 | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Junior Member
  • post

  • reply

  • points

    100

Latest Reply

Return to the list